SEC Form SC 13G/A filed by argenx SE (Amendment)

2/9/24 8:35:54 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ARGX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.9 ARGENX SE COMMON STOCK Cusip #N0610Q109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #N0610Q109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,017,222 Item 6: 0 Item 7: 4,173,842 Item 8: 0 Item 9: 4,173,842 Item 11: 7.064% Item 12: HC Cusip #N0610Q109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,173,842 Item 8: 0 Item 9: 4,173,842 Item 11: 7.064% Item 12: IN Item 1(a). Name of Issuer: ARGENX SE Item 1(b). Address of Issuer's Principal Executive Offices: INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052 ZWIJNAARDE , C9 B-9052 BE Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: N0610Q109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,173,842 (b) Percent of Class: 7.064% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,173,842 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ARGENX SE. No one other person's interest in the COMMON STOCK of ARGENX SE is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ARGENX SE at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ARGX alert in real time by email

Recent Analyst Ratings for

$ARGX

Date	Price Target	Rating	Analyst
7/8/2025		Hold → Buy	Deutsche Bank
7/3/2025	$700.00	Overweight	Morgan Stanley
5/13/2025	$680.00	Neutral → Outperform	Robert W. Baird
3/17/2025		Mkt Perform → Outperform	Bernstein
3/12/2025		Sell → Hold	Deutsche Bank
1/17/2025		Hold → Sell	Deutsche Bank
11/12/2024	$697.00	Peer Perform → Outperform	Wolfe Research
11/5/2024	$715.00	Sector Perform → Sector Outperform	Scotiabank

More analyst ratings

SEC Form SC 13G/A filed by argenx SE (Amendment)

2/9/24 8:35:54 AM ET

$ARGX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ARGX alert in real time by email

Recent Analyst Ratings for

$ARGX

Date	Price Target	Rating	Analyst
7/8/2025		Hold → Buy	Deutsche Bank
7/3/2025	$700.00	Overweight	Morgan Stanley
5/13/2025	$680.00	Neutral → Outperform	Robert W. Baird
3/17/2025		Mkt Perform → Outperform	Bernstein
3/12/2025		Sell → Hold	Deutsche Bank
1/17/2025		Hold → Sell	Deutsche Bank
11/12/2024	$697.00	Peer Perform → Outperform	Wolfe Research
11/5/2024	$715.00	Sector Perform → Sector Outperform	Scotiabank

More analyst ratings

SEC Form SC 13G/A filed by argenx SE (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$ARGX

SEC Form SC 13G/A filed by argenx SE (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$ARGX

$ARGX
Press Releases

Fastest customizable press release news feed in the world

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

$ARGX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

argenx upgraded by Deutsche Bank

Morgan Stanley resumed coverage on argenx with a new price target

argenx upgraded by Robert W. Baird with a new price target

$ARGX
SEC Filings

SEC Form 6-K filed by argenx SE

SEC Form 6-K filed by argenx SE

SEC Form 6-K filed by argenx SE

$ARGX
Leadership Updates

Live Leadership Updates

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

argenx Appoints Ana Cespedes to Board of Directors

argenx Appoints Camilla Sylvest to Board of Directors

$ARGX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by argenx SE

Amendment: SEC Form SC 13G/A filed by argenx SE